Core Viewpoint - The approval of Leping Medical's PLLA-based facial filler marks its entry into the dermatology field, expanding its business into the aesthetic medicine sector, which is expected to positively impact the company's growth [1][3]. Company Summary - Leping Medical has received NMPA registration approval for its self-developed PLLA facial filler, known as "童颜针" or "youthful needle," which is designed to stimulate collagen regeneration for skin rejuvenation [1][2]. - The product is characterized by its excellent biocompatibility, biodegradability, and safety, decomposing into carbon dioxide and water within the body [2]. - The company anticipates that this new product will contribute positively to its consumer healthcare business development [3]. Industry Summary - The Chinese aesthetic medicine market, particularly the regenerative injection segment, is projected to reach approximately 11.52 billion RMB by 2027, with a compound annual growth rate (CAGR) of about 31.2% from 2025 to 2027 [4]. - The market for "童颜针" is becoming increasingly competitive, with several products nearing approval, indicating a trend towards more diverse and effective regenerative injection products [4]. - Companies like Jiangsu Wuzhong and Aimeike have already seen significant revenue growth from their aesthetic products, highlighting the strong performance potential in this sector [2][3].

200亿市值医疗器械上市公司，获批医美产品。 据东吴商社吴劲草团队介绍，医美再生注射通常使用生物医用高分子材料作为主要成分，通常以微球形 式注射到真皮层或皮下组织中，从而实现美容和抗衰的目的。 6月3日晚间，国内心血管器械龙头乐普医疗（300003.SZ）发布公告称，公司于今日获悉，自主研发的 聚乳酸面部填充剂获得国家药品监督管理局（NMPA）注册批准。 据介绍，聚乳酸面部填充剂，即"童颜针"，是一种真皮组织填充剂，通过将聚左旋乳酸（PLLA）注射 于真皮深层，起到修复外形，矫正轮廓以达到填充沟壑、皱纹的效果。 公告显示，其主要成分聚左旋乳酸（PLLA）是一种微粒注射型粉末，具有优异的生物相容性、可降解 性和安全性，可在生物体内降解为二氧化碳和水排出体外，不会对人体造成长期影响。 对于此次获批，乐普医疗表示，"产品的成功获批上市是公司在皮肤科领域的重要里程碑事件，标志着 公司正式进入皮肤科领域，进一步助力公司消费医疗事业的健康发展，预计将对公司业务发展产生积极 作用。" 不过，该公司也提示风险称，新产品上市后在推广过程中具体销售情况可能受到包括但不限于临床推 广、渠道开拓、竞争格局改变、宏观政策等因素影响，该 ...